GSK CFO Interviewed on Q1 Results 2014

LONDON, April 30, 2014 /PRNewswire/ --

The global healthcare company GSK has unveiled 2014 Q1 results today, described by its CFO Simon Dingemans as encouraging across many areas mixed with some challenges, most notably in the US.

As a result, group sales fell in the quarter but the company managed to post bottom line growth of 2% as a result of operating leverage and financial efficiencies. The group declared a 6% increase in the dividend.

The period also saw the significant push by the company to rebalance its portfolio with the proposed asset swap with Novartis.   

The interview and transcript are available now on http://video.merchantcantos.com/companies/g/glaxosmithkline/

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email [email protected] or phone +44-(0)207-936-1352.

SOURCE GlaxoSmithKline

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.